• Profile
Close

Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: An observational study

BMC Cardiovascular Disorders Jan 22, 2019

Cosentino ER, et al. – Researchers investigated whether indacaterol/glycopyrronium therapy is a safe and efficacious treatment option for patients (n=56) with a history of heart failure (HF; New York Heart Association classes II and III) and stable chronic obstructive pulmonary disease (COPD). At baseline, as well as 6 months after therapy, participant blood samples, clinical assessment, echocardiograms and basal spirometry were assessed. Findings demonstrated that this therapy was well-tolerated and effective. Compared with baseline, a significant reduction in brain natriuretic peptide levels was noted after 6 months of treatment, as well as improved clinical status in a higher percentage of patients. Also, significant improvements were evident in all respiratory parameters (forced expiratory volume in 1 s [FEV1], FEV1/forced vital capacity ratio, and COPD Assessment Test scores). There were no hospitalizations owing to HF or COPD exacerbation. Death attributed to respiratory failure was reported for one patient.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay